Loading...
•
Sep 30, 2022
Matinas BioPharma Q3 2022 Earnings Report
Matinas BioPharma reported financial results for Q3 2022 and provided a corporate update.
Key Takeaways
Matinas BioPharma reported a net loss of $5.5 million for the third quarter of 2022. The company's cash, cash equivalents, and marketable securities were $33.1 million as of September 30, 2022, which is expected to fund operations through 2023. Key highlights include the successful completion of Phase 2 for MAT2203 and preparation for Phase 3.
EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen.
Phase 3 pivotal trial of MAT2203 for treatment of cryptococcal meningitis to commence Q1 2023.
The Infectious Diseases Society of America (IDSA) chose EnACT as its Outstanding Abstract and IDSA Awardee at IDWeek 2022.
Eric J. Ende, MD, MBA was appointed as Chairman of the Board effective October 1, 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...